- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06159777
Präoperatives Polyethylenglykol 3350 für die minimalinvasive urogynäkologische Chirurgie
Prä- und postoperativ im Vergleich zu postoperativem reinem Polyethylenglykol 3350 für minimalinvasive urogynäkologische Chirurgie
The goal of this clinical trial is to test the use of a laxative before surgery in women having surgery to fix pelvic prolapse that do not have constipation.
The main question it aims to answer is: Does use of a laxative before surgery lessen the discomfort of bowel movements after surgery? Participants will be asked to complete questionnaires before and after surgery. Researchers will compare using the laxative before and after surgery versus only after surgery to see if there is less discomfort with bowel movements after surgery.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
The purpose of this study is to evaluate if there is a difference in bother related to constipation between a pre-operative versus post-operative start of a bowel regimen for patients undergoing surgery for pelvic organ prolapse This will be a multi-institution, single-blind, randomized control trial utilizing questionnaires and chart review to evaluate effect of pre-operative bowel regimen on post-operative constipation.
- Study team and surgeons will be blinded to group assignments, participants will not be.
- Participants will be randomized after consent is obtained, and at least 1 week prior to planned surgery, via computer-generated blocks in a 1:1 ratio between study group (pre-operative and post-operative use) and control group (post-operative only use) of polyethylene glycol 3350 (PEG)
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- University Hospitals Cleveland Medical Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients assigned female sex at birth undergoing an apical prolapse procedure including: sacrocolpopexy, sacrospinous ligament suspension, uterosacral ligament suspension, or colpocleisis. Planned urogynecologic procedure may include hysterectomy, adnexectomy, colporrhaphy, perineorrhaphy, or treatment of stress urinary incontinence.
- Planning to undergo primary procedure as above via minimally invasive route: vaginal or laparoscopic (including robotic-assisted). Including those that have an unplanned conversion intraoperatively of minimally invasive route to open laparotomy.
Exclusion Criteria:
- Diagnosis of irritable bowel syndrome, inflammatory bowel disease, slow transit constipation, obstructed defecation, or symptomatic constipation at time of study screening and recruitment. (Slow transit constipation and obstructed defecation defined as per American Gastroenterological Association 2013 constipation statement. Symptomatic constipation defined as any of the following: Bristol Stool Scale score of 1 or 2, PAC-SYM score greater than 1.0, self-reported 2 or less bowel movements per week.)
- Current use of pharmacologic laxative agent ≥1x/week (prescription or OTC) for the treatment of constipation symptoms
- Allergy or intolerance to polyethylene glycol 3350
- Planning to undergo surgery via laparotomy
- Scheduled for any concurrent non-urogynecologic procedure, ex abdominoplasty
- History of large bowel resection, surgical treatment of constipation, or anal sphincter surgery
- History of sacral neuromodulation
- Current or prior radiation therapy to the abdomen or pelvis
- Current or prior diagnosis of malignancy
- Unable to provide informed consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Pre-operative
Participants will be instructed to take 17 grams of powder Polyethylene glycol 3350 (PEG) every day starting 3 days prior to scheduled surgery date and continue to take 17 grams of PEG every day for 7 days following the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used. |
*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Andere Namen:
|
|
Aktiver Komparator: Post-operative
Participants will be instructed to take 17 grams of powder PEG* every day for 7 days starting the day of surgery. Participants will be allowed to titrate up or down the amount of PEG used as needed and instructed to record all doses of PEG used. |
*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PAC-SYM
Zeitfenster: Pre-operative, 1 week post-operative, 2 weeks post-operative
|
Patient assessment of constipation symptoms (PAC-SYM) is a validated 12-item questionnaire with reported average score 0-4. Higher scores indicate more constipation symptoms |
Pre-operative, 1 week post-operative, 2 weeks post-operative
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PAC-QOL: Patient Assessment of Constipation Quality of Life Measure
Zeitfenster: 2 weeks post-operative
|
PAC-QOL is a 28-item questionnaire with scores averaged ranging from 0-4 without units. Higher scores signify worse constipation symptoms. |
2 weeks post-operative
|
|
Time to First Bowel Movement
Zeitfenster: 1 week post-operative
|
after surgery in approximate days |
1 week post-operative
|
|
Doses of PEG Used
Zeitfenster: 1 week post-operative, 2 weeks post-operative
|
polyethylene glycol 3350 (PEG) doses of 17 grams powder mixed in 8oz of liquid |
1 week post-operative, 2 weeks post-operative
|
|
Number of Participants With Rescue Laxative Use
Zeitfenster: 1 week post-operative, 2 weeks post-operative
|
Use of additional laxatives or enemas |
1 week post-operative, 2 weeks post-operative
|
|
Satisfaction With Pain After Surgery
Zeitfenster: 1 week post-operative
|
Satisfaction with pain after surgery, 0-10 Likert scale (0=not at all satisfied, 10= completely satisfied) |
1 week post-operative
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: David Sheyn, MD, University Hospitals Cleveland Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- STUDY20231417
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .